Triplet Therapeutics Appoints Kathy Biberstein, J.D., and Stephen Webster to its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc., a biotechnology company leveraging insights from the human genetics of repeat expansion disorders (REDs), today announced the appointments of Kathy Biberstein, J.D., and Stephen Webster to its board of directors. Ms. Biberstein brings extensive legal, policy and operations expertise in the global biopharma industry, most recently serving as Executive Vice President, Chief Administrative & Legal Officer, Chief Compliance & Risk Officer and Board Secretary at Alkermes. Mr. Webster brings deep experience in capital markets and financial management, most recently serving as Chief Financial Officer at Spark Therapeutics.

“I am so pleased to welcome Kathy and Stephen to Triplet’s board. They bring a wealth of experience across legal, strategic, financial and operational functions that will be critical as we drive toward transformational new treatments for REDs,” said Nessan Bermingham, Ph.D., Triplet’s chief executive officer, president, and founder. “Kathy has spent much of her career helping to advance new therapeutics for diseases of the central nervous system, and Stephen has led fundraising and managed financial and investor relations across multiple biotech companies. We look forward to drawing on both of their expertise.”

Ms. Biberstein and Mr. Webster join existing board members Nessan Bermingham, Ph.D., Jean-François Formela, M.D., Shinichiro Fuse, Ph.D., Douglas Kerr, M.D., Ph.D., MBA, and Nikola Trbovic, Ph.D.

“I am delighted to join and work alongside the highly talented team at Triplet,” said Ms. Biberstein. “Novel therapies to treat neurological diseases are badly needed. The innovative approach Triplet is developing has the potential to be transformative for people living with REDs, and I look forward to supporting the company as it progresses.”

During her 15-year tenure at Alkermes, Ms. Biberstein was responsible for a wide range of functions across legal, intellectual property, government affairs, policy and operations. As General Counsel, she established the legal function and held operational and strategic roles in major licensing and mergers and acquisitions transactions. She was instrumental in the company’s nearly $1 billion merger with Elan Drug Technologies. Ms. Biberstein currently serves as an observer on the Investment Committees of the UBS Oncology Impact Fund and Oncology Impact Fund 2 and on the Biopharma Advisory Team of FocusMaine. She received her B.S. in mechanical-electrical engineering from Kettering University and her J.D. from the University of Michigan Law School.

“I’m tremendously honored to join Triplet’s board, especially at a time when the company is poised to make important progress as it works to advance a new therapeutic approach for REDs,” said Mr. Webster. “Having led a wide range of biopharmaceutical companies through strategic growth milestones, I’m excited to bring my experience and help Triplet realize the full potential of its platform.”

During his tenure at Spark Therapeutics, Mr. Webster served as the Chief Financial Officer, notably leading its IPO in 2015. Prior to joining Spark, he was Senior Vice President, Finance, and Chief Financial Officer at Optimer Pharmaceuticals and Adolor Corporation, both of which were acquired by Cubist Pharmaceuticals. He held the role of President and CEO at Neuronyx, of which he was a co-founder. Mr. Webster also has experience in investment banking, previously serving as Managing Director at Broadpoint Capital and Director at PaineWebber (now UBS). He received his A.B. in economics from Dartmouth College and his MBA from The Wharton School of the University of Pennsylvania.

About Triplet Therapeutics

Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) – a group of more than 50 known genetic diseases including myotonic dystrophy type 1 (DM1), Huntington’s disease (HD), spinocerebellar ataxias (SCAs), fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) – leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs.

Triplet is headquartered in Cambridge, Mass. For more information, please visit www.triplettx.com.